Abstract
The cholinergic hypothesis of Alzheimers disease has spurred the development of numerous structural classes of compounds with different pharmacological profiles aimed at increasing central cholinergic neurotransmission, thus providing a symptomatic treatment for this disease. Indeed, the only drugs currently approved for the treatment of Alzheimers disease are cholinomimetics with the pharmacological profile of acetylcholinesterase inhibitors. Recent evidence of a potential disease modifying role of acetylcholinesterase inhibitors and M1 muscarinic agonists have led to a revival of this approach, which might be considered as more than a symptomatic treatment.
Keywords: Cholinergic Drugs, Alzheimers disease, muscarinic agonists, acetylcholine (ACh), Potassium Channel Blockers, Aminoacridines, N-Benzylpiperidines, xanomeline, muscarine
Mini-Reviews in Medicinal Chemistry
Title: Cholinergic Drugs in Pharmacotherapy of Alzheimers Disease
Volume: 2 Issue: 1
Author(s): Pelayo Camps and Diego Munoz-Torrero
Affiliation:
Keywords: Cholinergic Drugs, Alzheimers disease, muscarinic agonists, acetylcholine (ACh), Potassium Channel Blockers, Aminoacridines, N-Benzylpiperidines, xanomeline, muscarine
Abstract: The cholinergic hypothesis of Alzheimers disease has spurred the development of numerous structural classes of compounds with different pharmacological profiles aimed at increasing central cholinergic neurotransmission, thus providing a symptomatic treatment for this disease. Indeed, the only drugs currently approved for the treatment of Alzheimers disease are cholinomimetics with the pharmacological profile of acetylcholinesterase inhibitors. Recent evidence of a potential disease modifying role of acetylcholinesterase inhibitors and M1 muscarinic agonists have led to a revival of this approach, which might be considered as more than a symptomatic treatment.
Export Options
About this article
Cite this article as:
Camps Pelayo and Munoz-Torrero Diego, Cholinergic Drugs in Pharmacotherapy of Alzheimers Disease, Mini-Reviews in Medicinal Chemistry 2002; 2 (1) . https://dx.doi.org/10.2174/1389557023406638
DOI https://dx.doi.org/10.2174/1389557023406638 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
From Bone Marrow Transplantation to Cellular Therapies: Possible Therapeutic Strategies in Managing Autoimmune Disorders
Current Pharmaceutical Design Withdrawal Notice: A Rough Set Based Approach to Compute The Impact of Non-Academic Parameters on Academic Performance
Recent Advances in Computer Science and Communications GSTP1 Polymorphisms and their Association with Glutathione Transferase and Peroxidase Activities in Patients with Motor Neuron Disease
CNS & Neurological Disorders - Drug Targets AMPK as a Potential Anticancer Target - Friend or Foe?
Current Pharmaceutical Design Review of Current Chemoinformatic Tools for Modeling Important Aspects of CYPsmediated Drug Metabolism. Integrating Metabolism Data with Other Biological Profiles to Enhance Drug Discovery
Current Drug Metabolism 21-Hydroxy-6,19-epoxyprogesterone: A Promising Therapeutic Agent and a Molecular Tool for Deciphering Glucocorticoid Action
Mini-Reviews in Medicinal Chemistry Neuroprotective Effects of Quercetin: From Chemistry to Medicine
CNS & Neurological Disorders - Drug Targets Serotonin as a Modulator of Immune Function: An Overview
Current Immunology Reviews (Discontinued) Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: New Targets for Future Antidepressants
Current Neuropharmacology Editorial (Thematic Issue: Future Trends in the Development of New Antidepressant Drugs)
Current Pharmaceutical Design Brain Proton Magnetic Resonance Spectroscopy: A Review of Main Metabolites and its Clinical Applications in Gliomas
Current Molecular Imaging (Discontinued) Retinoic Acid Induced 1, RAI1: A Dosage Sensitive Gene Related to Neurobehavioral Alterations Including Autistic Behavior
Current Genomics Neuroprotection by Alpha 2-Adrenergic Agonists in Cerebral Ischemia
Current Neuropharmacology Recent Patents in Cell-Based Strategies for Soft Tissue Engineering in Plastic and Reconstructive Surgery
Recent Patents on Biomedical Engineering (Discontinued) Editorial: Seeking Answers to Questions in Adolescent Psychiatry
Adolescent Psychiatry Prognostic and Predictive Molecular Markers in Cutaneous Malignant Melanoma: The First Step Toward Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Dense Gas Technology and Cyclodextrins: State of the Art and Potential
Current Organic Chemistry High Sensitivity C-Reactive Protein (hsCRP): A New Biochemical Marker of Atherosclerotic Vascular Disease
Current Cardiology Reviews Melatonin Leads to Axonal Regeneration, Reduction in Oxidative Stress, and Improved Functional Recovery Following Sciatic Nerve Injury
Current Neurovascular Research Rexinoids as Therapeutics for Alzheimer’s Disease: Role of APOE
Current Topics in Medicinal Chemistry